| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Non-Customized |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Bortezomib is the first proteasome inhibitor to be used clinically. Proteasomes are present in all eukaryotic cells and degrade more than 80% of intracellular proteins. It reversibly inhibits the function of the proteasome, thereby inhibiting protein degradation, leading to protein accumulation and cell apoptosis. Because multiple myeloma (MM) continuously replicates and secretes myeloma proteins, it is more sensitive to the proteasome than normal cells and can be used as a second-line treatment for MM and mantle cell lymphoma.
Bortezomib is the first proteasome inhibitor approved by the US FDA for multiple myeloma, a blood cancer. A reversible 26S proteasome inhibitor, a barrel-shaped multiprotein particle present in the nucleus and cytoplasm of all eukaryotic cells. Targeting the ubiquitin-proteasome pathway.
Bortezomib is a new targeted drug for myeloma. The discovery of the drug has attracted widespread attention in the pharmaceutical industry. Its mechanism of action won the Nobel Prize in Chemistry in 2004. 2Chemicalbook won the highest honor in the pharmaceutical industry in 2006 - the International Galen Award ( PrixGalien), hailed as "a revolution in tumor treatment and a major advancement in the treatment of multiple myeloma"
Multiple international clinical studies have proven that bortezomib-containing regimens are significantly more effective than traditional chemotherapy regimens and can significantly increase patients' complete remission rate, prolong their survival, and improve their quality of life. Bortezomib is used throughout the entire induction, consolidation, and maintenance treatment of myeloma, and has become the preferred first-line treatment for myeloma.
){kind=link}